Protein and molecular recognition Flashcards

1
Q

SH2 domains

A
  • 100 amino acids
  • two antiparallel beta strands surrounded by 2 helices
  • phosphotyrosine binds as an extended strand
  • there are conserved Arg/Lys residues that contribute to interact with the negative tyrosine
  • variable residues contribute to specificity
  • two binding pockets:
    1. for the phosphotyrosine (conferring selectivity for the activate RTK/EGFR receptor)
    2. for the downstream binding peptide (conferring sequence specificity to that protein)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Grb2

A
  • one SH2 and two SH3 domains

- function– recruit Sos

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Gbr2-Sos interaction

A
  • the SH3 domain of Grb2 consists of 5 anti-parallel beta strands a a group of aromatic residues forming a hydrophobic patch
  • the SH3 binds a left handed poly-proline helix (consensus=PxxP)
  • the specificities of individual SH3 domains are different due to two charged variable loops
  • as the binding surface of Grb2 is hydrophobic, the interactions between it and the hydrophobic Sos are strong and permanent !!
  • 9 proline residues bind to a long groove in Grb2
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Sos-Ras interaction

A
  • binding is through a large interface– mainly hydrogen bonds and electrophilic interactions
  • binding causes a change in the Ras nucleotide binding site (this releases GDP)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

conformational changes in Ras

A

Ras has different conformations depending on which nucleotide is present;
the difference is because of conformational changes in two regions (“switch” 1 and 2) which form hydrogen bond with the “gamma” (third) phosphate of GTP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what does the GTPase activity of Ras require

A
  • GAP

- inserts Arg residue in the active site to stimulate hydrolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Binding between Ras and Raf

A
  • an intermolecular beta sheet (extending the anti-parallel beta sheet in both)
  • Raf has NO direct contact with the GTP; Raf only contacts one of the switches which change conformation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Raf

A
  • Ser/Thr kinase
  • N terminal inhibitory domain loops back and blocks the catalytic domain normally
  • Ras binds to inhibitory domain and displaces it, allowing activation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Fos and Jun

A
  • DNA binding proteins causing transcription of growth factor responsive genes
  • leucine zippers

bonds:

  • hydrophobic interactions between the helices
  • non-specific ionic interactions with phosphate backbone
  • specific H bonds with base pairs (in the major groove)–>this gives the specificity of promoter interaction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

binding specificity of antibodies

A
  • determined by CDR sequence
  • CDR3 is the most variable
  • variability is achieved through recombination
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

FcgR (g=>gamma)

A
  • it is a receptor on cell that binds the CH2 and CH3 constant domains of the antibody IgG
  • leads to phagocytosis or cytotoxicity– mediated by the cell that expresses the receptor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

FcRn

A

-is a receptor expressed in neonates that protects IgG from degradation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

complement cascade and constant domains

A
  • the constant domains of Ig are recognised by the first component of complement (C1q)
  • conformational change and proteolysis leads to activation of the complement cascade and activation of the membrane attack complex
  • the membrane attack complex forms pores in the cell and leads to lysis and inflammation response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is the concept behind immunity to flu

A
  • haemagglutinin binds sialic acid on target

- immunity comes from antibodies that block the site that binds to the sialic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

human antibody fragments? their role?

A
  • FAb–>(contain VL, CL, VH, and CH1)
  • Fv–>(contains VL and VH)
  • scFv–>(also contains VL and VH but with a peptide linker)

-used in drugs to bind to pathogens or toxins and simply block their function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

humira (adalimumab)

A
  • therapeutic antibody generated from phage display
  • prevents TNF binding to its receptor
  • used for autoimmune diseases (RA, crohns, psoriasis)
17
Q

mechanism of action of humira

A
  • reduced TNF-alpha activity
  • reduces the expression of TNF inducible genes
  • decreases inflammation
  • decreased angiogenesis and invasion of basement membrane
18
Q

Herceptin (Trastuzumab)

A
  • is a drug used in chemotherapy
  • it binds to ErbB2 near membrane and doesn’t disrupt dimerization
  • thought to cause receptor-mediated internalisation
  • also mediates antibody dependant cytotoxicity
19
Q

which cancers is EGFR involved in?

A

-Colorectal, head and neck etc.

20
Q

Cetuximab

A

chimaeric antibody to ErbB2

disrupt dimerization

21
Q

Pertuzumab

A

humanised antibody to ErbB2

disrupt dimerization

22
Q

Panitumumab

A

Transgenic mice dervied antibody to Erb2

disrupt dimerization

23
Q

ErbB2

A
  • it is a member of EGF family
  • it doesn’t have a ligand binding domain to bind to GFs
  • but, it can bind tightly to other EGFRs to form a heterodimer
  • this stabilizes the ligand binding and enhances the signalling pathway
  • overexpression of ErbB2 has been proposed in various cancers (incl. breast)
24
Q

what’s antibody-dependant cytotoxicity?

A

-a cell mediated immune defense whereby an effector cell lyses a target cell whose membrane-surface antigens have been bound by specific antibodies

25
Q

Erlotinib (Tarceva)

A

-EGF receptor kinase inhibitor
-competes with ATP for binding the active site
(ATP forms H bonds with some residues and binds weakly; tarceva has many hydrophobic interactions–binds 100x more tightly)

26
Q

Vemurafinib

A
  • it’s a Raf inhibitor used in treatment of melanoma once the V600E mutation has been confirmed by sequencing;
  • it is generated by fragment-based drug theory

around half malignant melanomas have a Raf (V600E) inhibitor– Val in the activation loop is replaced by a Glu; this leads to activated Raf without a signal